From 23 June 2025, access to the medication tirzepatide (Mounjaro®) is beginning in England for a small number of patients living with obesity who are at the highest risk of serious health conditions.
In the Black Country, new community-based weight management services are currently being developed to support safe and effective access to this treatment, this means GPs are not yet able to prescribe tirzepatide (Mounjaro®) for weight management in this area.
We’re working quickly to make these services available. As part of our phased approach, the first group of patients who may be eligible will include those who:
- Have a BMI of 40 or more (or 37.5 for people from minority ethnic backgrounds),
- And have obstructive sleep apnoea on CPAP (or where CPAP is not suitable or tolerated),
- And have at least three of the following long-term conditions:
- Type 2 diabetes
- High blood pressure (hypertension)
- Cardiovascular disease
- Dyslipidaemia
Other patients who meet the broader NHS criteria (BMI ≥ 40 and four or more related health conditions) may become eligible in later stages.
Please see Black Country ICB for more information.